Anti-Human Amyloid-β (Aducanumab) – Fc Muted™

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Aducanumab. Aducanumab, is a high-affinity, fully human IgG1 monoclonal antibody that specifically targets aggregated forms of amyloid-β (Aβ) in the brain.

Amyloid-β (Aβ) is a peptide that accumulates in the brains of individuals with Alzheimer’s disease, forming plaques that are a hallmark of the condition. These plaques are believed to contribute to the neurodegenerative processes seen in Alzheimer’s by disrupting cell function and triggering inflammatory responses. Amyloid-β is derived from the amyloid precursor protein (APP) through enzymatic cleavage. The aggregation of Aβ into oligomers and fibrils is a key pathological feature of Alzheimer’s disease, making it a significant target for therapeutic interventions aimed at reducing or preventing plaque formation 1,2^1,2.

Aducanumab is a human monoclonal antibody of the IgG1 isotype that specifically targets aggregated forms of amyloid-β. Developed by Biogen and Neurimmune, Aducanumab was designed to bind to amyloid plaques in the brain, facilitating their clearance by the immune system. Clinical studies have shown that Aducanumab can reduce amyloid plaque levels in patients with early Alzheimer’s disease, potentially slowing cognitive decline. The development of Aducanumab involved identifying antibodies from healthy elderly individuals who were cognitively normal, leveraging their immune response to create a therapeutic antibody^2-4.

Amyloid-β (Aβ) is primarily found in the brain, where it accumulates to form plaques in individuals with Alzheimer’s disease.

APBB1-KAT5, TNFRSF21, binds transient metals such as copper, zinc, and iron

1. Arndt JW, Qian F, Smith BA, et al. Sci Rep. 2018;8(1):6412.
2. Sevigny J, Chiao P, Bussière T, et al. Nature. 2016;537(7618):50-56.
3. Rahman A, Hossen MA, Chowdhury MFI, et al. Psychogeriatrics. 2023;23(3):512-522.
4. Lin L, Hua F, Salinas C, et al. CPT Pharmacometrics Syst Pharmacol. 2022;11(3):362-372.
5. Desvignes C, Edupuganti SR, Darrouzain F, et al. Bioanalysis. 2015;7(10):1253-1260.